Compare Moderna, Inc. (MRNA) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Wynn Resorts, Limited — how do they compare? Moderna, Inc. trades at $137.23 (market cap $56.02B), while Wynn Resorts, Limited trades at $90.11 (market cap $9.50B). The key difference: Moderna, Inc. is far larger — about 5.9× Wynn Resorts, Limited's market cap, and Wynn Resorts, Limited pays a 1.08% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | WYNN | |
|---|---|---|
Market Cap | $56.02B | $9.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $174.38 | $133.34 |
52-Week Low | $22.36 | $90.23 |
Enterprise Value | $52.17B | $19.74B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Wynn Resorts (WYNN) trades at $92.22, up 0.74% today, with a bearish technical signal and mixed earnings. Q2 2026 EPS beat estimates at $1.24, but Q4 2025 and Q1 2026 missed. Revenue reached $7.14B in 2025, with net income margin at 6.06%. Recent news highlights Macau strength offset by U.S. margin pressure and rising capital expenditures for new projects.
Outlook: Analyst consensus is bullish with a $132.44 price target, but risks include high debt ($10.5B long-term), profit margin compression, and significant capital spending. The stock offers growth potential from Macau recovery and new developments, yet faces headwinds from operational costs and leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
